iCAD, Inc. (ICAD)

Market Cap	105.87M
Revenue (ttm)	19.53M
Net Income (ttm)	-5.23M
Shares Out	27.29M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,826
Open	3.920
Previous Close	3.890
Day's Range	3.790 - 3.938
52-Week Range	1.190 - 4.015
Beta	1.38
Analysts	Hold
Price Target	n/a
Earnings Date	Aug 12, 2025

About ICAD

iCAD, Inc. provides AI-powered cancer detection solutions in the United States. The company’s ProFound Breast Health Suite offers solutions for breast cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications; and enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Detection solutions include advanced artificial intelligence and image analysis workflow solu...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Dec 3, 1986
• Employees: 66
• Stock Exchange: NASDAQ
• Ticker Symbol: ICAD
• Website: https://www.icadmed.com

Financial Performance

In 2024, iCAD, Inc.'s revenue was $19.61 million, an increase of 13.22% compared to the previous year's $17.32 million. Losses were -$5.62 million, 15.9% more than in 2023.